Comparison tool

Eptifibatide vs Desmopressin side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

EptifibatideDesmopressin

Share this peptide comparison

Property	Eptifibatide	Desmopressin
Category	Other	Hormonal
Also known as	Integrilin	DDAVP, Stimate, Minirin
FDA approved	Yes	Yes
Clinical status	FDA Approved - Acute coronary syndrome and PCI Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	FDA Approved - Multiple indications Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Heart procedure support, clot prevention	Bedwetting, diabetes insipidus, bleeding disorders
How it works	Eptifibatide is described as a reversible glycoprotein IIb/IIIa receptor antagonist on platelets. The supplied mechanism evidence links its KGD motif to receptor binding, which interferes with fibrinogen bridging between platelets and reduces aggregation. The source also reports a plasma half-life of roughly 2.5 hours, supporting a comparatively short duration of antiplatelet activity after discontinuation.	Desmopressin is described as a V2-selective vasopressin receptor agonist. In renal collecting ducts, V2 activation raises intracellular signaling that moves aquaporin water channels into place, allowing more water to be reabsorbed and producing smaller volumes of more concentrated urine. The source also notes that desmopressin has much less V1-mediated blood-vessel constriction than vasopressin. In endothelial tissue, V2 activity can increase release of stored von Willebrand factor and factor VIII, linking the same receptor system to hemostatic effects in selected bleeding disorders.
Typical dosing	Limited community data available · See research protocols	Limited community data available · See research protocols
Research dosing	180 mcg/kg IV bolus · Up to 72 hours · IV bolus and infusion	10-40 mcg intranasal · Varies by condition · Intranasal, oral, IV, or subcutaneous
Typical duration	Up to 72 hours	Varies by condition
Administration	IV bolus and infusion	Intranasal, oral, IV, or subcutaneous
Timing	Morning or as directed With or without food	Morning or as directed With or without food
Evidence level	FDA Approved	FDA Approved
Possible side effects	Bleeding (Reported as the most common listed effect, with a 28% figure in the source.) Major bleeding (Source reports a 3-10% range.) Hypotension +4 more Thrombocytopenia Allergic reactions High-risk medication per ISMP (Listed as a high-risk medication designation in the source.) FDA approved (Integrilin) (This is a regulatory or identity note from the source, not a side effect.)	Headache (Listed as common in the source.) Hyponatremia (Highlighted as a major risk.) Water intoxication (Source notes that severe cases can involve seizures.) +3 more Nausea Nasal congestion (Associated with spray use in the source.) Thrombotic events (Listed as rare in the source.)
Research summary	The supplied research summary characterizes Eptifibatide as supported by large randomized human trials. It cites PURSUIT in non-ST-elevation acute coronary syndrome, where death or nonfatal myocardial infarction was lower versus placebo, and ESPRIT in stenting, where the 30-day composite of death, myocardial infarction, or urgent revascularization was reported as about 6.8% with Eptifibatide versus 10.4% with placebo. The same evidence emphasizes bleeding as the principal tradeoff and reports that thrombocytopenia and immunogenicity were not common findings in that summary.	The source characterizes desmopressin as a long-used approved medicine rather than an experimental peptide. It reports clinical relevance in central diabetes insipidus, nocturnal enuresis, and nocturia through reduced urine production. It also describes hemostatic use because desmopressin can raise von Willebrand factor and factor VIII, with relevance to von Willebrand disease, mild hemophilia A, and some procedure-related contexts. The main safety issue emphasized is dilutional hyponatremia from retained water, with higher concern in young children and older adults according to the supplied source.
References	PubMed NCBI Bookshelf +2 more PubMed PubMed	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Eptifibatide

Desmopressin

Category

Other

Hormonal

Also known as

Integrilin

DDAVP, Stimate, Minirin

FDA approved

Yes

Clinical status

FDA Approved - Acute coronary syndrome and PCI

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

FDA Approved - Multiple indications

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Heart procedure support, clot prevention

Bedwetting, diabetes insipidus, bleeding disorders

How it works

Eptifibatide is described as a reversible glycoprotein IIb/IIIa receptor antagonist on platelets. The supplied mechanism evidence links its KGD motif to receptor binding, which interferes with fibrinogen bridging between platelets and reduces aggregation. The source also reports a plasma half-life of roughly 2.5 hours, supporting a comparatively short duration of antiplatelet activity after discontinuation.

Desmopressin is described as a V2-selective vasopressin receptor agonist. In renal collecting ducts, V2 activation raises intracellular signaling that moves aquaporin water channels into place, allowing more water to be reabsorbed and producing smaller volumes of more concentrated urine. The source also notes that desmopressin has much less V1-mediated blood-vessel constriction than vasopressin. In endothelial tissue, V2 activity can increase release of stored von Willebrand factor and factor VIII, linking the same receptor system to hemostatic effects in selected bleeding disorders.

Typical dosing

Limited community data available · See research protocols

Research dosing

180 mcg/kg IV bolus · Up to 72 hours · IV bolus and infusion

10-40 mcg intranasal · Varies by condition · Intranasal, oral, IV, or subcutaneous

Typical duration

Up to 72 hours

Varies by condition

Administration

IV bolus and infusion

Intranasal, oral, IV, or subcutaneous

Timing

Morning or as directed

With or without food

Morning or as directed

With or without food

Evidence level

FDA Approved

Possible side effects

Bleeding (Reported as the most common listed effect, with a 28% figure in the source.)
Major bleeding (Source reports a 3-10% range.)
Hypotension

+4 more

Thrombocytopenia
Allergic reactions
High-risk medication per ISMP (Listed as a high-risk medication designation in the source.)
FDA approved (Integrilin) (This is a regulatory or identity note from the source, not a side effect.)

Headache (Listed as common in the source.)
Hyponatremia (Highlighted as a major risk.)
Water intoxication (Source notes that severe cases can involve seizures.)

+3 more

Nausea
Nasal congestion (Associated with spray use in the source.)
Thrombotic events (Listed as rare in the source.)

Research summary

The supplied research summary characterizes Eptifibatide as supported by large randomized human trials. It cites PURSUIT in non-ST-elevation acute coronary syndrome, where death or nonfatal myocardial infarction was lower versus placebo, and ESPRIT in stenting, where the 30-day composite of death, myocardial infarction, or urgent revascularization was reported as about 6.8% with Eptifibatide versus 10.4% with placebo. The same evidence emphasizes bleeding as the principal tradeoff and reports that thrombocytopenia and immunogenicity were not common findings in that summary.

The source characterizes desmopressin as a long-used approved medicine rather than an experimental peptide. It reports clinical relevance in central diabetes insipidus, nocturnal enuresis, and nocturia through reduced urine production. It also describes hemostatic use because desmopressin can raise von Willebrand factor and factor VIII, with relevance to von Willebrand disease, mild hemophilia A, and some procedure-related contexts. The main safety issue emphasized is dilutional hyponatremia from retained water, with higher concern in young children and older adults according to the supplied source.

References

PubMed NCBI Bookshelf

+2 more

+2 more

Full profile